NCT00501592 - Study of INT-747 in Patients With Diabetes and Presumed NAFLD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

April 30, 2009

Conditions

Diabetes Mellitus, Type IIFatty Liver

Interventions

DRUG

INT-747

25 mg by mouth once daily, 50 mg by mouth once daily

DRUG

Placebo

Trial Locations (4)

Virginia Commonwelath University, Richmond

Diabetes & Glandular Disease Research Associates, Inc., San Antonio

Profil Institute for Clinical Research, Inc., Chula Vista

UC San Diego VAMC, San Diego